The interaction of chloramphenicol and beta-cyclodextrin (beta-CD) in aqueous solution was studied using resonance Rayleigh scattering (RRS) technology. The molar ratio of the inclusion complex was 1:1 established by spectrophotometry. The RRS technology was first applied to the determination of the inclusion constant of chloramphenicol to beta-CD. The RRS peak of chloramphenicol was at 331 nm. When beta-CD interacted with chloramphenicol to form an inclusion complex, the RRS intensity was enhanced and increased with an increase in beta-CD concentration. The inclusion constants at different temperatures were measured by the RRS technology. The determination results using the RRS technology corresponded with those of the UV-spectrophotometric method. Therefore, the RRS method can be used as a new technology for the determination of the inclusion constant. The thermodynamic parameters (DeltaH, DeltaS and DeltaG) associated with the inclusion process were also determined. These values indicated that van der waals forces and hydrogen bonding could be considered as a main driving force for the encapsulation of chloramphenicol by beta-CD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.talanta.2004.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence.
J Antimicrob Chemother
January 2025
Institutes of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, China.
Objectives: Amikacin is crucial for treating Mycobacterium abscessus (Mab) infections, with resistance primarily attributed to rrs gene mutations. The correlation between specific mutations and amikacin susceptibility, along with the associated fitness cost, requires further investigation.
Methods: We isolated spontaneous amikacin-resistant mutants in vitro and identified their mutation sites in the rrs gene via Sanger sequencing, which were then compared with existing reports.
Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.
Front Immunol
January 2025
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
Background: Telitacicept, a new biological agent, was approved in China for treating systemic lupus erythematosus (SLE) in 2021. Its optimal dosing for treating SLE remains unclear. Therefore, the aim of this meta-analysis is to evaluate the efficacy and safety of various telitacicept doses in SLE treatment.
View Article and Find Full Text PDFClinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials.
Ann Med
December 2025
Heart Centre, Turku University Hospital, Turku, Finland.
Background: Several randomized controlled trials (RCTs) have investigated the benefits of atrial fibrillation (AF) screening. However, since none have shown a significant reduction in stroke rates, the impact of screening on clinical outcomes remains uncertain.
Materials And Methods: We conducted a systematic review and meta-analysis of RCTs reporting clinical outcomes of systematic AF screening in participants without known AF.
Sex Differences in Long COVID.
JAMA Netw Open
January 2025
University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Importance: A substantial number of individuals worldwide experience long COVID, or post-COVID condition. Other postviral and autoimmune conditions have a female predominance, but whether the same is true for long COVID, especially within different subgroups, is uncertain.
Objective: To evaluate sex differences in the risk of developing long COVID among adults with SARS-CoV-2 infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!